The private-equity owners of Biomet - which include Blackstone (BX), KKR (KKR) and Goldman...
Monday, July 1, 9:50 AM ET
The private-equity owners of Biomet - which include Blackstone (BX), KKR (KKR) and Goldman Sachs' (GS) P-E fund - are reportedly considering an IPO for the artificial hip and knee maker six years after taking it private for $11.4B. Since then, annual revenues have increased to $3B from $2.1B and EBITDA to $946M from $587M, while debt has fallen to $5.9B from $6.3B. Given that rival Stryker is valued at around 8.5X EBITDA, Biomet's theoretical value could be $8B, meaning that the P-E firms are set to make a loss.
